Pharmaceutical Technology, Feb 1, 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Feb 1, 2013
Articles
Building Toolboxes through Cross-Functional Partnerships
By Patricia Van Arnum
When speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.
The State of Outsourcing Partnerships
By Jim Miller
Preferred-provider relationships are transforming the bio/pharmaceutical industry.
CROs in a Global State of Mind
By Patricia Van Arnum
CROs are keeping pace with the increased globalization of the biopharmaceutical/pharmaceutical industry through a combination of acquisitions, partnerships, and select investments.
Achieving More Effective and Efficient GMP Auditing
By Stefan Kettelhoit , Martin van Trieste
Adherence to GMP in API manufacturing is crucial in determining the safety of drug products.
Survey: Optimizing Global Biopharmaceutical Operations Through Risk Mitigation and Management
By Phil Kaminsky , Jiyang Liu , Julia Olsen-Claire
A UC Berkeley survey provides insight into biopharma's risk concerns and strategies.
The Future of BioPharma
By Eric Langer
Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends.
Seeking Strength in Partnership Strategies
By Patricia Van Arnum
In the arena of pharmaceutical outsourcing, when speaking of partnerships, the discussion typically focuses on the relationship between a pharmaceutical/biopharmaceutical company as the sponsor company and a contract-service provider.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here